On Invalid Date, Gyre Therapeutics (NASDAQ: GYRE) reported Q4 2023 earnings per share (EPS) of $0.09, up 100.59% year over year. Total Gyre Therapeutics earnings for the quarter were -$89.15 million. In the same quarter last year, Gyre Therapeutics's earnings per share (EPS) was -$15.26.
As of Q1 2024, Gyre Therapeutics's earnings has grown year over year. Gyre Therapeutics's earnings in the past year totalled -$92.93 million.
What is GYRE's earnings date?
Gyre Therapeutics's earnings date is Invalid Date. Add GYRE to your watchlist to be reminded of GYRE's next earnings announcement.
What was GYRE's revenue last quarter?
On Invalid Date, Gyre Therapeutics (NASDAQ: GYRE) reported Q4 2023 revenue of $113.45 million up 11.78% year over year. In the same quarter last year, Gyre Therapeutics's revenue was $101.50 million.
What was GYRE's revenue growth in the past year?
As of Q1 2024, Gyre Therapeutics's revenue has grown 10.91% year over year. This is 154.7 percentage points lower than the US Biotechnology industry revenue growth rate of 165.61%. Gyre Therapeutics's revenue in the past year totalled $113.45 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.